ICU Medical (ICUI)
Builds infusion pumps, IV consumables, and vital-care devices for clinical workflows.
Something off on this page? Send us feedback.
Supplies hospitals and other care settings with IV consumables, infusion pumps and software, and vital-care devices, generating revenue from product and service sales. Operates as one segment, while sterile IV solutions are sold and distributed through its Otsuka joint-venture relationship.
Develops and manufactures infusion therapy, vascular access, and vital-care products for hospitals, clinics, home-care providers, and long-term-care facilities. Consumables include IV sets, needlefree connectors, catheters, hazardous-drug transfer systems, and tracheostomy products. Infusion Systems pairs large-volume, syringe, and ambulatory pumps with dedicated sets, medication-safety software, and professional services. Vital Care covers anesthesia, respiratory, hemodynamic monitoring, temperature-management, and pain-management products.
Sells worldwide through direct teams and distributors, with the portfolio managed as one reportable segment. Pump platforms and their dedicated disposables support integrated medication-delivery workflows. Sterile IV solutions are distributed for the Otsuka ICU Medical joint venture rather than owned as a controlled business. Medical-device approvals and quality systems govern commercialization; manufacturing is concentrated in the United States, Costa Rica, Mexico, and the Czech Republic, with some components sourced from single or limited suppliers.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 7, 2026 | Needham | Reiterate | Rating: —Target: $165 | Target: $187 |
| Aug 7, 2026 | BTIG | Reiterate | Rating: —Target: $170 | Target: $200 |
| Aug 7, 2026 | Raymond James | Reiterate | Rating: —Target: $97 | Target: $200 |
| Jul 21, 2026 | KeyBanc | Reiterate | Rating: —Target: $164 | Target: $182 |
| Jun 15, 2026 | BTIG | Target | Target: — | Target: $170 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $298.3M · Total debt $1.27B · Total assets $3.97B · Shareholders' equity $2.15B
- Revenue
- $551.7M
- Operating income
- $39.1M
- Net income
- $19.1M
No dividends on record.
| Institutions | 105.49% | 26.38M shares | |
|---|---|---|---|
| 293 holders · as of Jun 30, 2026 | |||
| Insiders | 10.35% | 2.59M shares | |
| 13 holders · as of Sep 3, 2026 | |||
| Strategic holders | 9.88% | 2.47M shares | |
| 1 holder · as of Aug 14, 2025 | |||
| Adds to | 125.72% | ||
25.01M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 125.72%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 15.01% | 3.75M | as of Jun 30, 2026 |
Jupiter Topco LLCInstitution | 11.12% | 2.78M | as of Jun 30, 2026 |
Janus Henderson Group PLCStrategic | 9.88% | 2.47M | filed Aug 14, 2025 |
T. Rowe Price Investment Management, Inc.Institution | 9.71% | 2.43M | filed Aug 10, 2022 |
Ein #.Insider | 9.18% | 2.29M | filed Feb 10, 2022 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 3, 2026 | Virginia Ruth Sanzone | officer: VP, General Counsel | −4,856 | $168.69 |
| Sep 1, 2026 | Brian Michael Bonnell | officer: Chief Financial Officer | −6,381 | $175.00 |
| Aug 31, 2026 | Brian Michael Bonnell | officer: Chief Financial Officer | −9,307 | $172.79 |
| Aug 13, 2026 | Daniel Woolson | officer: VP, GM-Infusion Capital | −5,417 | $181.33 |
| Aug 12, 2026 | Ben Sousa | officer: Chief Information Officer | −2,250 | $178.32 |
- BD
Broad overlap in infusion systems, access, and monitoring
- Baxter International
Major IV therapy rival across pumps, fluids, and sets
- Teleflex
Vascular-access and acute-care consumables overlap
- Medtronic
Vital-care overlap in monitoring, airway, and warming
- AngioDynamics
Focused vascular-access and specialty-consumables rival
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| ICU Medical | $164.93 | +2.45% | $4.02B | 136.4 | 18.6 | 1.9 | −0.2% |
| BD | $182.91 | −0.05% | $50.42B | 55.1 | 13.8 | 2.4 | −9.6% |
| Baxter International | $23.68 | −0.02% | $12.24B | — | 11.2 | 1.1 | +5.3% |
| Teleflex | $124.48 | −0.34% | $5.53B | — | 13.4 | 2.1 | −27.0% |
| Medtronic | $90.64 | −0.14% | $116.19B | 22.4 | 15.1 | 3.1 | +13.7% |
| AngioDynamics | $15.75 | +0.53% | $647.7M | — | — | 2.0 | +8.1% |
| Median | 38.7 | 13.6 | 2.1 | +5.3% |